A director at SSAB AB maiden bought 9,955 shares at 4.505EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
>Solid results again in Q3 thanks to strong price discipline - SSAB released yesterday another set of solid results in Q3, with EBITDA of SEK 2.3bn beating the consensus by 11% despite falling sharply from Q2 (-43%) because of particularly strong seasonality amid a general economic slowdown and extensive maintenance activity. These results were marked again by resilient prices (except in US plates), a reflection of the group’s more premium positioning and prudent mar...
>Résultats T3 de nouveau solides grâce à une bonne discipline de prix - SSAB a publié hier une nouvelle série de solides résultats T3 avec un EBITDA de 2,3 MdSEK supérieur de 11% au consensus bien qu’en forte baisse vs T2 (-43%) à cause d’une saisonnalité particulièrement marquée dans un contexte de ralentissement économique généralisé et d’activité importante de maintenance. La publication a de nouveau été marquée par une bonne résilience des prix (hormis dans les pl...
The strong Q3 results show that SSAB is in a unique position, and thanks to its large and growing exposure to special steel and premium steel, the earnings outlook is much more stable and attractive than most others given companies in the industry. In addition, we also like the transformative investments into fossil-free steel-making. Having said this, SSAB is not immune to the market headwind. We reiterate our HOLD and have trimmed our target price to SEK54 (55).
Last week, we organised an Expert Access event on multiple sclerosis (MS) with the participation of Dr Géraldine Androdias, a neurologist at Lyon University Hospital. Dr Androdias presented the key points of the ECTRIMS 2024 conference, as well as new trends in treating the illness. We note an unmet need in the primary progressive and secondary progressive forms, a real interest for the BTKi class with the greater penetration of the blood-brain barrier, and expectations for the anti-C...
Nous avons organisé la semaine dernière un Expert Access autour de la sclérose en plaques (SEP) avec la participation du Dr Géraldine Androdias, médecin neurologue au CHU de Lyon. Le Dr Androdias a présenté les points saillants du congrès de l’ECTRIMS 2024 ainsi que les nouvelles tendances dans la prise en charge de la maladie. Nous retenons un besoin insatisfait dans les formes progressives et secondairement progressives, un vrai intérêt de la classe des BTKi avec le passage accru de...
>Better-than-expected print as very sticky prices offset weaker volumes - SSAB delivered decent Q3 results with EBITDA at SEK 2.3bn, 11% above consensus and 9% ODDO BHF. Net result was a stronger beat at SEK 1.0bn, 21% above consensus and 38% ODDO BHF. EBITDA was still down 43% q-o-q at the lowest in four years as volumes contracted well beyond the usual seasonality but prices proved very resilient overall thanks to the high-end positioning and the cautious commercial...
>Better-than-expected print as very sticky prices offset weaker volumes - SSAB delivered decent Q3 results with EBITDA at SEK 2.3bn, 11% above consensus and 9% ODDO BHF. Net result was a stronger beat at SEK 1.0bn, 21% above consensus and 38% ODDO BHF. EBITDA was still down 43% q-o-q at the lowest in four years as volumes contracted well beyond the usual seasonality but prices proved very resilient overall thanks to the high-end positioning and the cautious commercial...
We have cut our 2024–2025e earnings again, mainly due to a more cautious view on steel prices in general but US plate in particular. While we remain confident in the longer-term outlook for earnings, dividends and transformational investments, we expect industry newsflow to remain negative at least until the end of the year, and are increasingly concerned about SSAB’s Q4 earnings. As a result, we have cut our target price to SEK55 (85) and downgraded to HOLD (BUY).
>Solid Q2 results thanks to good price discipline - SSAB yesterday reported solid Q2 results, with EBITDA of SEK 4bn (-2.5% vs Q1) and net income of SEK 2.4bn (-6%) fully in line with expectations. Volume performance was below the guidance issued at the end of Q1 due to a wait-and-see attitude on the part of customers. By contrast, prices turned out to be better than expected in all three main divisions, including US plates, where the recent fall in spot market prices...
>Résultats T2 solides grâce à une bonne discipline de prix - SSAB a publié hier des résultats T2 solides avec un EBITDA de 4 MdSEK (-2,5% vs T1) et un résultat net de 2,4 MdSEK (-6%) totalement en ligne avec les attentes. La performance en termes de volumes a été inférieure aux indications données à l’issue du T1 en raison de l’attentisme des clients. En revanche, les prix se sont révélés supérieurs aux attentes dans les trois principales divisions y compris dans les ...
The Q2 report was solid across the board, but headwinds from lower prices and volumes in Q3 are likely to be more pronounced than expected. Reflecting this and SSAB’s slightly more cautious view on prices, we have cut our 2024–2025e EBITDA by 7–4%. However, we still see an attractive investment case, as it continues to offer appealing earnings multiples and offers plenty of cash on the balance sheet. We also expect the weakness in many of its markets to bottom out in Q3. We reiterate our BUY, bu...
>Q2 in line and stable on Q1 thanks to Europe normalisation - SSAB delivered solid Q2 results with EBITDA at SEK 4.0bn, in line with consensus and 14% above ODDO BHF. Net result also came in line with consensus at SEK 2.4bn. Q2 EBITDA edged down 2% vs Q1 as normalization in Europe (from the weak Q1 level) was more than offset by weaker trends in the two other core Special Steels and Americas divisions. Europe benefitted from the end of the strike (SEK125m impact vs S...
>Q2 in line and stable on Q1 thanks to Europe normalisation - SSAB delivered solid Q2 results with EBITDA at SEK 4.0bn, in line with consensus and 14% above ODDO BHF. Net result also came in line with consensus at SEK 2.4bn. Q2 EBITDA edged down 2% vs Q1 as normalization in Europe (from the weak Q1 level) was more than offset by weaker trends in the two other core Special Steels and Americas divisions. Europe benefitted from the end of the strike (SEK125m impact vs S...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.